Social, economic, and health utility considerations in the treatment of overactive bladder

Open Access Journal of Urology

Volumn 2, Issue 1, 2010, Pages 11-24

  Sacco, Emilio ^a   Tienforti, D'Aniele ^a   Pinto, Francesco ^a   Racioppi, Marco ^a   Totaro, Angelo ^a   D'Agostino, D'Aniele ^a   Marangi, Francesco ^a   Bassi, Pierfrancesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Burden; Cost utility; Health utility; Overactive bladder

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE;

ADL DISABILITY; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLADDER RECONSTRUCTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH STATUS; HUMAN; IDIOPATHIC DISEASE; NEUROMODULATION; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PSYCHOMETRY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SOCIAL ASPECT; SOCIOECONOMICS; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE;

EID: 77953434448     PISSN: None     EISSN: 11791551     Source Type: Book Series    
DOI: 10.2147/oaju.s4166     Document Type: Review

References (139)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167-178.
2. Chu FM, Dmochowski R. Pathophysiology of overactive bladder. Am J Med. 2006;119(3 Suppl 1):3-8.
3. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760-766.
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20: 327-336.
5. Tubaro A, Palleschi G. Overactive bladder: epidemiology and social impact. Curr Opin Obstet Gynecol. 2005;17:507-511.
6. Serels S. The wet patient: understanding patients with overactive bladder and incontinence. Curr Med Res Opin. 2004;20:791-801.
7. Ricci JA, Baggish JS, Hunt TL, et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther. 2001;23:1245-1259.
8. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in 5 countries: results of the EPIC study. Eur Urol. 2006;50:1306-1315.
9. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6:S574-S579.
10. Norton PA, MacDonald LD, Sedgwick PM, Stanton SL. Distress and delay associated with urinary incontinence, frequency, and urgency in women. BMJ. 1988;297:1187-1189.
11. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl): S580-S590.
12. Johannesson M, O'Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol. 1997;80:557-562.
13. Lenderking WR, Nackley JF, Anderson RB, et al. A review of the quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics. 1996;9:11-23.
14. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of over-active bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97: 96-100.
15. Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy. 2005;25:511-519.
16. Zorn BH, Montgomery H, Pieper K, et al. Urinary incontinence and depression. J Urol. 1999;162:82-84.
17. Brown JS, Subak LL, Gras J, et al. Urge incontinence: The patient's perspective. J Women's Health. 1998;7:1263-1269.
18. Stewart W, Van Rooyen JB, Cundiff G, et al. Prevalence and burden of overactive in the United States. World J Urol. 2003;20:327-336
19. Robinson D, Pearce KF, Preisser JS, et al. Relationship between patient reports of urinary incontinence symptoms and quality of life measures. Obstet Gynecol. 1998;91:224-228.
20. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology. 2001;57:1044-1050.
21. Michel MC, de la Rosette JJ, Piro M, Schneider T. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol. 2005;48:110-115.
22. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7:455-463.
23. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101: 1388-1395.
24. Ponholzer A, Temml C, Obermayr R, et al. Association between lower urinary tract symptoms and erectile dysfunction. Urology. 2004;64: 772-776.
25. Frankel SJ, Donovan JL, Peters TI, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol. 1998;51:677-685.
26. Irwin DE, Milsom I, Reilly K, et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med. 2008;5:2904-2910.
27. Aslan G, Cavus E, Karas H, Oner O, Duran F, Esen A. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl. 2006;52:155-162.
28. Coyne KS, Margolis MK, Jumadilova Z, Bavendam T, Mueller E, Rogers R. Overactive bladder and women's sexual health: what is the impact? J Sex Med. 2007;4:656-666.
29. Yip SK, Chan A, Pang S, et al. The impact of urodynamic stress incontinence and detrusor overactivity on marital relationship and sexual function. Am J Obstet Gynecol. 2003;188:1244-1248.
30. Cohen BL, Barboglio P, Gousse A. The impact of lower urinary tract symptoms and urinary incontinence on female sexual dysfunction using a validated instrument. J Sex Med. 2008;5:1418-1423.
31. Irwin DE, Milsom I, Reilly K, et al. Overactive bladder symptoms associated with a negative impact on work productivity: results from the EPIC study. International Continence Society. Christchurch, New Zealand. 2006. URL: http://www.icsoffice.org/publications/2006/pdf/0432.pdf. Accessed Jul 15, 2009.
32. Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98-S107.
33. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
34. Coyne KS, Matza LS, Brewster-Jordan J. "We have to stop again?!": The impact of overactive bladder on family members. Neurourol Urodyn. 2009;28:969-975.
35. Coyne KS, Matza LS, Brewster-Jordan J, Thompson C, Bavendam T. The psychometric validation of the OAB family impact measure (OAB-FIM). Neurourol Urodynam. 2009. [Epub Mar 9].
36. Basra R, Kelleher C. Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments. Pharmacoeconomic. 2007;25:129-142.
37. Donovan J, Badia X, Corcos J, et al. Committee 6: symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, et al, (eds): Incontinence. Plymouth, United Kingdom: Plymbridge Distributors, Ltd; 2002:267-316.
38. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53:46-50.
39. Komaroff AL, Fagioli LR, Doolittle TH, et al. Health status in patients with chronic fatigue Syndrome and in general population and disease comparison groups. Am J Med. 1996;101:281-290.
40. Kobelt G. Economic consideration and outcome measurement in urge incontinence. J Urol. 1997;50(Suppl 6A):100-107.
41. Currie CJ, McEwan P, Poole CD, Odeyemi IA, Datta SN, Morgan CL. The impact of the overactive bladder on health-related utility and quality of life. BJU Int. 2006;97:1267-1272.
42. Johannesson M, O'Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol. 1997;80:557-562.
43. O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence. Quality of life and patients' valuation of symptom reduction. Pharmacoeconomics. 1998;14:531-539.
44. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an over-active bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11:563-574.
45. Abrams P, Avery K, Gardener N, et al. The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol. 2006;175:1063-1066.
46. Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 2005;14:849-855.
47. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1997;104:988-993.
48. Reese PR, Pleil AM, Okano GJ, et al. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overac-tive bladder. Qual Life Res. 2003;12:427-442.
49. Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. BJU. 1996;77:805-812.
50. Donovan J, Abrams P, Peters T, et al. The ICS-'BPH' study: the psychometric validity and reliability of the ICSmale questionnaire. BJU. 1996;77:554-562.
51. Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res. 1994;3:291-306.
52. Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urology. 1996;47:67-71.
53. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn. 2005;24:215-225.
54. Matza LS, Zyczynski TM, Bavendam T. A review of quality-of-life questionnaires for urinary incontinence and overactive bladder: which ones to use and why? Curr Urol Rep. 2004;5:336-342.
55. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology. 1998;51:355-361.
56. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmacoeconomics. 2006;24:869-890.
57. Hu TW, Wagner TH. Economic considerations in overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S591-S598.
58. Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med. 2006;119(3 Suppl 1): 29-36.
59. Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU Int. 2007;99(3):502-509.
60. Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with overactive bladder: work loss burden. J Occup Environ Med. 2005;47:439-446.
61. Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology. 2006;68(2 Suppl):3-8.
62. Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98:398-406.
63. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States; a comparative study. Urology. 2004;63:461-465.
64. Hu TW. Impact of urinary incontinence on health-care costs. J Am Geriatr Soc. 1990;38:292-295.
65. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61:1123-1128.
66. MacKay K, Hemmett L. Needs assessment of women with urinary incontinence in a district health authority. Br J Gen Pract. 2001;51:801-804.
67. Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. BJU Int. 2005;96(Suppl 1):43-45.
68. National Institutes of Health. Disease-Specific Estimates of Direct and Indirect Costs of Illness and NIH Support. Bethesda, Maryland, US Public Health Services. 2000. URL: http://ospp.od.nih.gov/ecostudies/COIreportweb.htm. Accessed Jul 15, 2009.
69. Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care. 2009; 15(4 Suppl):S90-S97.
70. Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009;103:202-209.
71. Cartwright R, Renganathan A, Cardozo L. Current management of overactive bladder. Curr Opin Obstet Gynecol. 2008;20:489-495.
72. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350:786-799.
73. Bo K, Berghmans LC. Nonpharmacologic treatments for overactive bladder-pelvic floor exercises. Urology. 2000;55:7-11.
74. Brubaker L. Electrical stimulation in overactive bladder. Urology. 2000;55:17-23.
75. Cardozo LD. Biofeedback in overactive bladder. Urology. 2000;55: 24-28.
76. Payne CK. Behavioral therapy for overactive bladder. Urology. 2000; 55:3-6.
77. Sacco E, Pinto F, Bassi P. Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(4):583-598.
78. Andersson KE. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology. 2004;63(Suppl 3A):32-41.
79. Appell RA. The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve Clin J Med. 2002;69:761-769.
80. Cannon TW, Chancellor MB. Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynecol. 2002;45: 205-217.
81. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J Am Geriatr Soc. 1998;46:8-13.
82. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs. 2004;64:1643-1656.
83. Drutz H, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunction. 1999; 10:283-289.
84. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc. 2001;76:358-363.
85. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687-695.
86. Sussman G, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Med Res Opin. 2002;19: 177-184.
87. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005;47:376-384.
88. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol. 2005;48:464-470.
89. Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005;95:580-586.
90. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9:1787-1796.
91. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196-200.
92. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231-2236.
93. Ghei M, Maraj BH, Miller R, et al. Effects of botulinumtoxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005;174:1873-1877.
94. Sacco E, Paolillo M, Totaro A, et al. Botulinum toxin in the treatment of overactive bladder. Urologia. 2008;75:1-10.
95. Di Stasi SM, Giannantoni A, Vespasiani G, Navarra P, Capelli G, Massoud R, et al. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. J Urol. 2001;165:491-498.
96. Gauruder-Burmester A, Biskupskie A, Rosahl A, Tunn R. Electro-motive Drug Administration for Treatment of Therapy-Refractory Overactive Bladder. Int Braz J Urol. 2008;34:758-764.
97. Janknegt RA, Hassouna MM, Siegel SW, et al. Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol. 2001;39:101-106.
98. Das AK, Carlson AM, Hull M. Improvement in depression and health-related quality of life after sacral nerve stimulation therapy for treatment of voiding dysfunction. Urology. 2004;64:62-68.
99. Hijaz A, Vasavada S. Complications and troubleshooting of sacral neuromodulation therapy. Urol Clin North Am. 2005;32:65-69.
100. Busse R, Orvain J, Velasco M, et al. Best practice in undertaking and reporting health technology assessments. Int J Technol Assess Health Care. 2002;18:361-422.
101. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. NICE. 2004. URL: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf. Accessed Jul 15, 2009.
102. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-1475.
103. Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econom. 1986;5:1-30.
104. Rodriguez LV, Blander DS, Dorey F, Raz S, Zimmern P. Discrepancy in patient and physician perception of patient's quality of life related to urinary symptoms. Urology. 2003;62:49-53.
105. Prieto LS. Problems and solutions in calculating quality-adjusted life years (QALYs). Health and Quality of Life Outcomes. 2003;1:80.
106. Mortimer D, Segal L. Comparing the incomparable? a systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making. 2008;28: 66-89.
107. Kobelt G, Jönsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn. 1998;17:599-611.
108. Milsom I, Axelsen S, Kulseng-Hansen S, Mattiasson A, Nilsson CG, Wickstrøm J. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obstet Gynecol Scand. 2009;88:693-699.
109. Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol. 2009;181: 2181-2186.
110. Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. A costutility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin. 2008;24:2173-2179.
111. O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther. 2001;23:2038-2049.
112. Arnold D, Girling A, Stevens A, Lilford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009;339: b2688.
113. Brazier J, Roberts J, Deverill M. The estimation of a utility based algorithm from the SF-36 Health Survey. J Health Econ. 2002;21: 271-292.
114. EuroQol Group. URL: http://www.euroqol.org/home.html. Accessed Jul 15, 2009.
115. EuroQoL Group. EuroQoL -a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
116. Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess. 1999;3:1-164.
117. Yang Y, Brazier J, Tsuchiya A, Coyne, Karin P. Estimating a Preference-Based Single Index from the Overactive Bladder Questionnaire. Value Health. 2009;12:159-166.
118. Kok ET, McDonnell J, Stolk EA, Stoevelaar HJ, Busschbach JJ. The valuation of the International Prostate Symptom Score (IPSS) for use in economic evaluations. Eur Urol. 2002;42:491-497.
119. Stolk EA, Busschbach JJ. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res. 2003;12:363-371.
120. Brazier JE, Czoski-Murray C, Roberts J, et al. Estimation of a preference-based index from a condition specific measure: the King's Health Questionnaire. Med Decis Making. 2008;28:113-126.
121. Revicki DA, Leidy NK, Brennan F, et al. Development and preliminary validation of the multiattribute rhinitis symptom utility index. Qual Life Res. 1998;7:693-702.
122. Dowie J. Decision validity should determine whether generic or condition-specific HRQOL measure is used in health care decisions. Health Econ. 2002;11:1-8.
123. Capri S, Sormani MP, Lavezzari M, Velona T. Willingness to pay for reduced urge incontinence. Value in Health. 2000;3:304-305.
124. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics. 2004;22:1047-1059.
125. Getsios D, Caro JJ, Ishak KJ, El-Hadi W, Payne K. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin Ther. 2004; 26:431-438.
126. Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate-and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care. 2005;11(4 Suppl): S140-S149.
127. Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano RN. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface. 2000;13:88-94.
128. Guest JF, Abegunde D, Ruiz FJ. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Investig. 2004;24:305-321.
129. Getsios D, El-Hadi W, Caro I, Caro JJ. Pharmacological management of overactive bladder: a systematic and critical review of published economic evaluations. Pharmacoeconomics. 2005;23:995-1006.
130. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy. 2006;26:1694-1702.
131. Pelletier EM, Vats V, Clemens JQ. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Am J Manag Care. 2009;15(4 Suppl):S108-S114.
132. Sangster P, Kalsi V. Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity. BJU Int. 2008;102(Suppl 1):17-19.
133. Kalsi V, Popat RB, Apostolidis A, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol. 2005;49:519-527.
134. Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol. 2009;181: 2181-2186.
135. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437-452.
136. Aboseif SR, Kim DH, Rieder JM, et al. Sacral neuromodulation: cost considerations and clinical benefits. Urology. 2007;70:1069-1074.
137. Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48: 204-223.
138. Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 2009;15(4 Suppl):S118-S122.
139. Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 1999;83:583-590.